Published in FASEB J on July 18, 2002
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation (2008) 3.19
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol (2008) 2.46
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci (2006) 2.15
Microglial activation and chronic neurodegeneration. Neurotherapeutics (2010) 1.87
Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation (2008) 1.65
Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J Neurosci (2008) 1.48
Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol (2008) 1.45
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation (2004) 1.43
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis. J Virol (2009) 1.39
Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal (2010) 1.34
Tumor necrosis factor-alpha at the crossroads of neuronal life and death during HIV-associated dementia. J Neurochem (2003) 1.31
Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation (2007) 1.27
Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther (2008) 1.19
Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets (2011) 1.16
Effect of prolonged exposure to diesel engine exhaust on proinflammatory markers in different regions of the rat brain. Part Fibre Toxicol (2010) 1.15
The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. J Neurosci (2012) 1.14
Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol (2008) 1.13
Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther (2010) 1.10
Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain (2010) 1.10
Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J (2006) 1.09
Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases. Br J Pharmacol (2010) 1.08
The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics (2007) 1.07
Regulation of microglia effector functions by tumor necrosis factor signaling. Glia (2011) 1.04
Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS One (2011) 1.03
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis (2011) 1.00
Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. J Neuroinflammation (2010) 1.00
The role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelism. Int J Mol Sci (2012) 0.97
Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci (2008) 0.97
Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol (2010) 0.95
Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinsons Dis (2010) 0.95
Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease? Front Cell Neurosci (2013) 0.93
Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci (2015) 0.92
Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther (2011) 0.92
Glial tumor necrosis factor alpha (TNFα) generates metaplastic inhibition of spinal learning. PLoS One (2012) 0.92
Proteolytic activation of proapoptotic kinase protein kinase Cδ by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation (2012) 0.91
Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis (2011) 0.91
Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience (2007) 0.87
Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. J Neuroinflammation (2008) 0.86
Pesticides, microglial NOX2, and Parkinson's disease. J Biochem Mol Toxicol (2013) 0.86
Effects of naringin, a flavanone glycoside in grapefruits and citrus fruits, on the nigrostriatal dopaminergic projection in the adult brain. Neural Regen Res (2014) 0.85
Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J Mol Cell Biol (2014) 0.85
The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J Neuroinflammation (2011) 0.84
Rotenone and paraquat do not directly activate microglia or induce inflammatory cytokine release. Neurosci Lett (2009) 0.82
Ganoderma lucidum ethanol extract inhibits the inflammatory response by suppressing the NF-κB and toll-like receptor pathways in lipopolysaccharide-stimulated BV2 microglial cells. Exp Ther Med (2013) 0.82
Gestational lead exposure selectively decreases retinal dopamine amacrine cells and dopamine content in adult mice. Toxicol Appl Pharmacol (2011) 0.81
Microglial ion channels as potential targets for neuroprotection in Parkinson's disease. Neural Plast (2013) 0.81
Microglial phenotypes in Parkinson's disease and animal models of the disease. Prog Neurobiol (2016) 0.80
The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease. Int J Mol Sci (2011) 0.80
Reduced inflammatory phenotype in microglia derived from neonatal rat spinal cord versus brain. PLoS One (2014) 0.79
Neurotoxicity following acute inhalation of aerosols generated during resistance spot weld-bonding of carbon steel. Inhal Toxicol (2014) 0.79
Parkinson's disease and enhanced inflammatory response. Exp Biol Med (Maywood) (2015) 0.79
Brain region-specific gene expression profiles in freshly isolated rat microglia. Front Cell Neurosci (2015) 0.79
Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease. Mol Biol Cell (2015) 0.79
Dual effects of TNFalpha on nerve fiber formation from ventral mesencephalic organotypic tissue cultures. Brain Res (2008) 0.79
Necroptosis mediates TNF-induced toxicity of hippocampal neurons. Biomed Res Int (2014) 0.78
Modifying welding process parameters can reduce the neurotoxic potential of manganese-containing welding fumes. Toxicology (2014) 0.76
Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice. Int J Mol Sci (2016) 0.76
Glial-mediated inflammation underlying parkinsonism. Scientifica (Cairo) (2013) 0.75
TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease. Neural Regen Res (2016) 0.75
Kinin Peptides Enhance Inflammatory and Oxidative Responses Promoting Apoptosis in a Parkinson's Disease Cellular Model. Mediators Inflamm (2016) 0.75
Human pluripotent stem cell derived midbrain PITX3(eGFP/w) neurons: a versatile tool for pharmacological screening and neurodegenerative modeling. Front Cell Neurosci (2015) 0.75
Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases. Mediators Inflamm (2017) 0.75
The Anti-Inflammatory Activity of Eucommia ulmoides Oliv. Bark. Involves NF-κB Suppression and Nrf2-Dependent HO-1 Induction in BV-2 Microglial Cells. Biomol Ther (Seoul) (2016) 0.75
The role of TWEAK/Fn14 signaling in the MPTP-model of Parkinson's disease. Neuroscience (2016) 0.75
The Antioxidant Effects of Thymoquinone in Activated BV-2 Murine Microglial Cells. Neurochem Res (2016) 0.75
Reciprocal signals between microglia and neurons regulate α-synuclein secretion by exophagy through a neuronal cJUN-N-terminal kinase-signaling axis. J Neuroinflammation (2016) 0.75
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease. Front Aging Neurosci (2017) 0.75
Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid. Epidemiology (2013) 2.13
Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol (2002) 1.89
Telomere length, current perceived stress, and urinary stress hormones in women. Cancer Epidemiol Biomarkers Prev (2009) 1.88
Area under the curve and other summary indicators of repeated waking cortisol measurements. Psychosom Med (2007) 1.77
Neuroendocrine aspects of the response to stress. Metabolism (2002) 1.71
Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J (2006) 1.61
Cardiovascular effects of pulmonary exposure to single-wall carbon nanotubes. Environ Health Perspect (2006) 1.57
Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol (2009) 1.55
Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol (2007) 1.54
Work, obesity, and occupational safety and health. Am J Public Health (2007) 1.53
The Buffalo Cardio-Metabolic Occupational Police Stress (BCOPS) pilot study: methods and participant characteristics. Ann Epidemiol (2005) 1.50
Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem (2006) 1.49
Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci (2008) 1.48
Association of a dietary inflammatory index with inflammatory indices and metabolic syndrome among police officers. J Occup Environ Med (2014) 1.47
Physiological role of tumor necrosis factor alpha in traumatic muscle injury. FASEB J (2002) 1.42
Astrogliosis in CNS pathologies: is there a role for microglia? Mol Neurobiol (2010) 1.38
Arsenic and atherosclerosis. Toxicol Appl Pharmacol (2004) 1.33
Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol (2007) 1.31
Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ Health Perspect (2003) 1.22
The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling. Metab Brain Dis (2012) 1.21
Role of CC chemokines in skeletal muscle functional restoration after injury. Am J Physiol Cell Physiol (2004) 1.14
Nanotoxicology--a pathologist's perspective. Toxicol Pathol (2010) 1.10
c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem (2001) 1.08
Genotyping of single nucleotide polymorphisms in cytokine genes using real-time PCR allelic discrimination technology. Cytokine (2004) 1.07
Mechanism of age-dependent susceptibility and novel treatment strategy in glutaric acidemia type I. J Clin Invest (2007) 1.07
Inhalation of toluene diisocyanate vapor induces allergic rhinitis in mice. J Immunol (2007) 1.06
Defining "neuroinflammation". Ann N Y Acad Sci (2008) 1.05
Genotoxicity of multi-walled carbon nanotubes at occupationally relevant doses. Part Fibre Toxicol (2014) 1.05
Exposure and immunological determinants in a murine model for toluene diisocyanate (TDI) asthma. Toxicol Sci (2004) 1.04
Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphology. Proc Natl Acad Sci U S A (2008) 1.04
Sample-dependent effects on the neuropeptidome detected in rat brain tissue preparations by capillary liquid chromatography with tandem mass spectrometry. Anal Chem (2005) 1.03
A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain (2009) 1.02
Identification and quantification of neuropeptides in brain tissue by capillary liquid chromatography coupled off-line to MALDI-TOF and MALDI-TOF/TOF-MS. Anal Chem (2006) 1.00
Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine. J Neurochem (2012) 0.98
Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environ Health Perspect (2008) 0.98
Elevated environmental temperature and methamphetamine neurotoxicity. Environ Res (2003) 0.98
Cytokine polymorphisms in silicosis and other pneumoconioses. Mol Cell Biochem (2002) 0.98
Inflammatory mediators and skeletal muscle injury: a DNA microarray analysis. J Interferon Cytokine Res (2003) 0.97
Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine (2009) 0.97
Corticosterone primes the neuroinflammatory response to DFP in mice: potential animal model of Gulf War Illness. J Neurochem (2015) 0.96
Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol (2005) 0.95
Shiftwork duration and the awakening cortisol response among police officers. Chronobiol Int (2011) 0.95
The comparative immunotoxicity of five selected compounds following developmental or adult exposure. J Toxicol Environ Health B Crit Rev (2006) 0.95
Mild steel welding fume causes manganese accumulation and subtle neuroinflammatory changes but not overt neuronal damage in discrete brain regions of rats after short-term inhalation exposure. Neurotoxicology (2009) 0.94
Immune mediators in a murine model for occupational asthma: studies with toluene diisocyanate. Toxicol Sci (2004) 0.93
CTNNA3 (α-catenin) gene variants are associated with diisocyanate asthma: a replication study in a Caucasian worker population. Toxicol Sci (2012) 0.93
Low-level human equivalent gestational lead exposure produces supernormal scotopic electroretinograms, increased retinal neurogenesis, and decreased retinal dopamine utilization in rats. Environ Health Perspect (2008) 0.93
AMP-activated protein kinase phosphorylation in brain is dependent on method of killing and tissue preparation. J Neurochem (2007) 0.93
Systems analysis of genetic variation in MPTP neurotoxicity in mice. Neurotoxicology (2013) 0.92
Recapitulation of cell signaling events associated with astrogliosis using the brain slice preparation. J Neurochem (2006) 0.92
Pro-inflammatory interferon gamma signaling is directly associated with stroke induced neurodegeneration. J Neuroimmune Pharmacol (2014) 0.92
Do early-life insults contribute to the late-life development of Parkinson and Alzheimer diseases? Metabolism (2008) 0.92
NeuroAIDS, drug abuse, and inflammation: building collaborative research activities. J Neuroimmune Pharmacol (2006) 0.91
Thermoregulation and its influence on toxicity assessment. Toxicology (2007) 0.91
Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. Toxicol Sci (2013) 0.90
Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination. J Immunol (2003) 0.90
Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatum. J Neurochem (2011) 0.90
Cortisol patterns and brachial artery reactivity in a high stress environment. Psychiatry Res (2009) 0.89
Role of tumor necrosis factor in toluene diisocyanate asthma. Am J Respir Cell Mol Biol (2002) 0.89
IL-1beta gene polymorphisms influence hepatitis B vaccination. Vaccine (2002) 0.89
Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice. Vaccine (2005) 0.89
Conceptual heuristic models of the interrelationships between obesity and the occupational environment. Scand J Work Environ Health (2013) 0.88
Depression, cytokines, and glial function. Metabolism (2005) 0.88
Associations of cortical astrogliosis with cognitive performance and dementia status. J Alzheimers Dis (2004) 0.87
Calcium/calmodulin-dependent protein kinase II activity and expression are altered in the hippocampus of Pb2+-exposed rats. Brain Res (2005) 0.86
Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations. Vaccine (2013) 0.86
An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs (2008) 0.86
Autoantibodies to neurotypic and gliotypic proteins as biomarkers of neurotoxicity: assessment of trimethyltin (TMT). Neurotoxicology (2007) 0.86
Personalized medicine in major depressive disorder -- opportunities and pitfalls. Metabolism (2012) 0.85
Genetic susceptibility in pneumoconiosis. Toxicol Lett (2006) 0.85
Chronic treatment with supraphysiological levels of corticosterone enhances D-MDMA-induced dopaminergic neurotoxicity in the C57BL/6J female mouse. Brain Res (2002) 0.85
Association of osteoarthritis with serum levels of the environmental contaminants perfluorooctanoate and perfluorooctane sulfonate in a large Appalachian population. Am J Epidemiol (2011) 0.84
Adiposity, muscle, and physical activity: predictors of perturbations in heart rate variability. Am J Hum Biol (2013) 0.83
Selective changes in gene expression in cortical regions sensitive to amphetamine during the neurodegenerative process. Neurotoxicology (2004) 0.83
Symposium summary: children's health risk--what's so special about the developing immune system? Toxicol Appl Pharmacol (2004) 0.83
The pharmacology of wakefulness. Metabolism (2006) 0.83
Hexamethylene diisocyanate asthma is associated with genetic polymorphisms of CD14, IL-13, and IL-4 receptor α. J Allergy Clin Immunol (2011) 0.82